BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy

被引：0
|
作者：
A. S. Hamy
I. Bieche
J. Lehmann-Che
V. Scott
Ph. Bertheau
J. M. Guinebretière
M. C. Matthieu
B. Sigal-Zafrani
O. Tembo
M. Marty
B. Asselain
F. Spyratos
P. de Cremoux
机构：
[1] Institut Curie,Department of Biostatistics
[2] Institut Curie,Pharmacogenomics Unit, Department of Genetics
[3] Paris Diderot University,APHP Molecular Oncology Unit, Hôpital Saint Louis
[4] Institut Gustave Roussy,Biology Department
[5] Paris Diderot University,APHP Pathology Department, Hôpital Saint Louis
[6] Institut Curie,Pathology Department, Hôpital René
[7] Institut Gustave Roussy,Huguenin
[8] Institut Curie,Pathology Department
[9] Saint-Louis Hospital,Pathology Department
来源：
Breast Cancer Research and Treatment | 2016年 / 159卷
关键词：
Breast cancer; Neoadjuvant chemotherapy; Predictive;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：499 / 511
页数：12
相关论文
共 50 条
  • [1] BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy
    Hamy, A. S.
    Bieche, I.
    Lehmann-Che, J.
    Scott, V.
    Bertheau, Ph.
    Guinebretiere, J. M.
    Matthieu, M. C.
    Sigal-Zafrani, B.
    Tembo, O.
    Marty, M.
    Asselain, B.
    Spyratos, F.
    de Cremoux, P.
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 159 (03) : 499 - 511
  • [2] Tumor progression marker for breast cancer - survivin gene (BIRC5)
    Shlyakhtunou, Y.
    EUROPEAN JOURNAL OF CANCER, 2016, 61 : S104 - S105
  • [3] Prognostic Significance of BIRC5/Survivin in Breast Cancer: Results from Three Independent Cohorts
    Oparina, Nina
    Erlandsson, Malin C.
    Faldt Beding, Anna
    Parris, Toshima
    Helou, Khalil
    Karlsson, Per
    Einbeigi, Zakaria
    Bokarewa, Maria I.
    CANCERS, 2021, 13 (09)
  • [4] Do the survivin (BIRC5) splice variants modulate or add to the prognostic value of total survivin in breast cancer?
    Span, Paul N.
    Tjan-Heijnen, Vivianne C. G.
    Heuvel, Joop J. T. M.
    de Kok, Jacques B.
    Foekens, John A.
    Sweep, Fred C. G. J. .
    CLINICAL CHEMISTRY, 2006, 52 (09) : 1693 - 1700
  • [5] Survivin As a Predictive Biomarker of Complete Pathologic Response to Neoadjuvant Chemotherapy in Patients With Stage II and Stage III Breast Cancer
    Petrarca, Cristiane Rios
    Brunetto, Andre T.
    Duval, Vinicius
    Brondani, Adriana
    Carvalho, Gisele Pereira
    Garicochea, Bernardo
    CLINICAL BREAST CANCER, 2011, 11 (02) : 129 - 134
  • [6] Adenoid cystic carcinoma of the lacrimal gland: role of nuclear survivin (BIRC5) as a prognostic marker
    Mulay, Kaustubh
    Puthyapurayil, Fairooz M.
    Mohammad, Javed Ali
    Ali, Mohammad Hasnat
    Honavar, Santosh G.
    Reddy, Vijay Anand P.
    HISTOPATHOLOGY, 2013, 62 (06) : 840 - 846
  • [7] Cyclin E as a prognostic marker and predictor of response to neoadjuvant chemotherapy and adjuvant hormonal therapy in patients with stage II-III breast cancer
    Karakas, Cansu
    Francis, Ashleigh
    Yi, Min
    Sahin, Aysegul
    Keyomarsi, Khandan
    Hunt, Kelly
    CANCER RESEARCH, 2015, 75
  • [8] Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses
    Yang, Yaewon
    Im, Seock-Ah
    Keam, Bhumsuk
    Lee, Kyung-Hun
    Kim, Tae-Yong
    Suh, Koung Jin
    Ryu, Han Suk
    Moon, Hyeong-Gon
    Han, Sae-Won
    Oh, Do-Youn
    Han, Wonshik
    Kim, Tae-You
    Park, In Ae
    Noh, Dong-Young
    BMC CANCER, 2016, 16
  • [9] Neoadjuvant chemotherapy in the treatment of stage II and III breast cancer
    Singletary, SE
    AMERICAN JOURNAL OF SURGERY, 2001, 182 (04): : 341 - 346
  • [10] Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses
    Yaewon Yang
    Seock-Ah Im
    Bhumsuk Keam
    Kyung‑Hun Lee
    Tae‑Yong Kim
    Koung Jin Suh
    Han Suk Ryu
    Hyeong-Gon Moon
    Sae‑Won Han
    Do‑Youn Oh
    Wonshik Han
    Tae‑You Kim
    In Ae Park
    Dong-Young Noh
    BMC Cancer, 16
12345